LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the appointment of Vojo Vukovic M.D., Ph.D. as Vice President, Clinical Research. Reporting to Eric Jacobson, M.D., Senior Vice President and Chief Medical Officer, Dr. Vukovic will be the Synta medical lead for the Company’s most advanced oncology product candidate, elesclomol, and will support the implementation of a broad development strategy for elesclomol.
